Full-Time

National Strategic Account Executive

CG Oncology

CG Oncology

51-200 employees

Develops bladder cancer oncolytic immunotherapies

Compensation Overview

$204k - $240k/yr

+ Equity + Annual bonuses

Remote in USA

Remote

Category
Sales & Account Management (1)
Requirements
  • Bachelor's Degree required, MBA or other advanced degree preferred.
  • Minimum 10+ years in Managed Markets/Market Access
  • Minimum of 8+ years of demonstrated success in National Account roles across commercial and government payors.
  • Previous market access account responsibility for Biotech/Pharmaceutical launch required.
  • Strong launch experience with pre-PDUFA market preparation & planning
  • Demonstrated knowledge Medicare B and Buy & Bill payment models.
  • Extensive National Account relationships with a strong understanding of market access, reimbursement, and pricing landscape for pharmaceutical products, including Commercial/Medicare/Medicaid and other government and specialty segments.
  • Comprehensive understanding of the current and evolving payor landscape for complex therapies from both a Medical and Pharmacy benefit perspective.
  • Established customer relationships with Pharmacy Directors, Medical Directors, and other key personnel at National Payors.
  • Strong negotiation skills and a proven track record of engaging National Accounts at all relevant levels of the organization leading to successful attainment of desired formulary position.
  • Deep understanding of customer-specific review, approval, and reimbursement processes
  • Strong analytic acumen, displaying the ability to assess and identify business opportunities and challenges.
  • Experience developing and executing payer pull-through strategies in collaboration with field sales, sales leadership, medical, marketing, patient services, trade and distribution.
  • Highly accountable for the results and outcomes of their responsibilities and understands the impact of their efforts, results, and attitudes on others.
  • Forward thinking mindset with the ability to manage multiple projects and identify and resolve issues.
  • Urology and/or Oncology experience preferred.
Responsibilities
  • Collaborate with commercial leadership and senior management to develop and refine our corporate National Payor access strategies and provide input on contracting, pricing, and service offerings.
  • Develop and implement account specific business plans (roadmap, segmentation…) and tactics to support formulary placement, reimbursement (coverage, coding, payment, and patient access) pathways aligning to CG Oncology’s overall goals of securing patient access with National Payors.
  • Drive favorable access across assigned National Payors ensuring medical coverage policies are consistent with FDA approved prescribing information.
  • Initiate, lead and manage relationships with National Payors to appropriately influence the formulary review process, including the coordination of resources from Medical Affairs, Health Economics, and other cross-functional SMEs.
  • Develop, maintain, and execute pre-launch, and post-launch business and account plans across National Payor segments (Commercial/Medicare/Medicaid) including IDN’s in geographical region.
  • Leverage existing and/or established relationships at strategic National Payor Accounts, including the C- suite level, to create and communicate our value proposition.
  • Lead pricing and contracting negotiations with National Payors to ensure optimal market access, while delivering our value proposition and educating National Payor stakeholders on disease state, product, economic benefits, and reimbursement.
  • Broaden and deepen account relationships with C-Suite, Vice President of Network Management, Chief Medical Officer, Medical Director(s), Vice President of Pharmacy, Pharmacy Director(s) Clinical Managers and Case Managers. Develop relationships away from transactional to valued business partnerships.
  • Serve as the internal subject matter expert and primary point of contact for all National Account related issues, trends, market insights, risks, and opportunities; ensure relevant and timely payor coverage information is communicated to appropriate internal and external stakeholders.
  • Collaborate closely with Medical, Marketing, Patient Services and Distribution to develop support programs that will enhance our value proposition, removing barriers to access and assisting HCPs with understanding the National coverage environment providing appropriate patients a path to product and mitigating any access barriers.
  • Partner with Marketing, Patient Support Services, Medical and Sales to develop and communicate clear and effective customer pull through strategies and initiatives that support formulary placement and coverage.
  • Collaborate with field teams (Field Sales, FRM’s, Medical Affairs) to monitor the payer access environment to identify key trends, access barriers and partner with colleagues to mitigate.
  • Partner with HEOR to develop and execute our therapeutic value proposition messages that resonate with our National Payers
Desired Qualifications
  • MBA or other advanced degree preferred
  • Urology and/or Oncology experience preferred

CG Oncology develops immunotherapy treatments for bladder cancer, with a focus on preserving the bladder in patients with urologic cancers. Its lead product, cretostimogene grenadenorepvec, is delivered directly into the bladder to stimulate the immune system to attack non-muscle invasive bladder cancer that does not respond to BCG. The company concentrates on localized bladder cancer immunotherapy, differentiating itself by intravesical delivery and a focus on NMIBC, rather than broad systemic cancer drugs. Its goal is to improve quality of life for patients with NMIBC and other urologic cancers and move toward commercialization.

Company Size

51-200

Company Stage

IPO

Headquarters

Irvine, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • $903M cash funds operations into H1 2029 without dilution.
  • PIVOT-006 topline data expected H1 2026 accelerates approval path.
  • H.C. Wainwright targets $80/share citing strong safety data.

What critics are saying

  • FDA rejected cretostimogene BLA due to BOND-003 durability issues.
  • Merck's pembrolizumab captures 60% BCG-unresponsive NMIBC market.
  • $250M annual burn depletes cash by mid-2028 post-2026 readouts.

What makes CG Oncology unique

  • Cretostimogene grenadenorepvec delivers oncolytic immunotherapy intravesically for BCG-unresponsive NMIBC.
  • CG0070 targets Rb-defective bladder cancer cells via selective adenovirus replication.
  • First randomized Phase 3 trial in intermediate-risk NMIBC with PIVOT-006.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at CG Oncology who can refer or advise you

Benefits

Remote Work Options

Unlimited Paid Time Off

401(k) Company Match

401(k) Retirement Plan

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Performance Bonus

Health Savings Account/Flexible Spending Account

Company News

Yahoo Finance
Mar 15th, 2026
CG Oncology shares up 131% in a year as DCF model suggests 79% upside potential

CG Oncology has surged 131% over the past year, with shares climbing 54% year-to-date and 20% in the last month to reach $64.29. The cancer-focused biotech has attracted investor attention amid progress in its pipeline. A discounted cash flow analysis suggests the stock may still be undervalued. The model projects free cash flow will shift from losses of $225 million in 2026 and $200 million in 2027 to positive $21 million in 2028, $340 million in 2029 and $590 million in 2030, based on analyst estimates through 2030. The DCF model estimates an intrinsic value of $304 per share, implying the current price is 79% undervalued according to this cash flow-based approach. CG Oncology scores three out of six on valuation checks.

Yahoo Finance
Mar 6th, 2026
H.C. Wainwright raises CG Oncology price target to $80, eyes Phase 3 PIVOT-006 trial as key 2026 catalyst

H.C. Wainwright has raised its price target on CG Oncology to $80 from $75, maintaining a Buy rating. The analyst cited the company's progress toward a biologics application submission for cretostimogene in high-risk non-muscle invasive bladder cancer, supported by strong safety and durability data. CG Oncology reported FY25 revenue of $4.04 million, exceeding the $515,180 consensus estimate. The company expects topline data from its Phase 3 PIVOT-006 trial in intermediate-risk NMIBC in the coming months, which H.C. Wainwright identified as a key 2026 catalyst. CEO Arthur Kuan described PIVOT-006 as the first randomised registrational trial evaluating an investigational therapy in intermediate-risk NMIBC. Results from the CORE-008 study evaluating cretostimogene combined with gemcitabine are expected next quarter.

Yahoo Finance
Feb 27th, 2026
CG Oncology expects PIVOT-006 Phase 3 data in H1 2026 with $903M cash to fund ops into 2029

CG Oncology reported its 2025 financial results, highlighting approximately $903 million in cash, cash equivalents and marketable securities, sufficient to fund operations into the first half of 2029. The company expects topline data from its PIVOT-006 Phase 3 trial evaluating cretostimogene as adjuvant therapy in intermediate-risk non-muscle invasive bladder cancer in the first half of 2026, nearly a year ahead of schedule. PIVOT-006 is the first randomised Phase 3 trial in this patient population. First results from CORE-008 Cohort CX, evaluating cretostimogene combined with gemcitabine in high-risk non-muscle invasive bladder cancer, are also expected in the first half of 2026. The company strengthened its board in November 2025 with the addition of Christina Rossi, former chief operating officer of Blueprint Medicines.

Business News Today
Apr 28th, 2025
CG Oncology reports best-in-disease durability data for cretostimogene at AUA 2025

CG Oncology reports best-in-disease durability data for cretostimogene at AUA 2025.

DealForma
Mar 19th, 2025
CG Oncology Raises $437M in IPO

In 2024, biopharma therapeutics and platforms saw significant IPO activity, raising $6.8 billion across 26 IPOs. Notable IPOs include CG Oncology's $437M in January, Kyverna Therapeutics' $367M in February, Bicara Therapeutics' $362M in August, Septerna's $331M in October, and Upstream Bio's $293M in September. Overall, the sector experienced increased deal activity and higher capital raised compared to 2023, indicating a stronger financing environment.